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Background
Filoviruses, comprised of the Ebola viruses (EBOV) and
Marburg virus (MARV), are highly pathogenic agents
with human case fatality rates up to 90%. Periodic filo-
virus outbreaks occur in endemic regions of sub-
Saharan Africa, and a new pathogenic EBOV species
was discovered as recently as 2008, following an out-
break in Uganda. Additionally, these viruses are consid-
ered Category A biodefense pathogens. There exists an
urgent need to develop effective antiviral therapeutics
and vaccines to protect both civilian and military popu-
lations at risk of exposure. Our aim was to identify and
develop effective antisense-based therapeutics for treat-
ment of filovirus infections. We have previously shown
that synthetic antisense phosphorodiamidate morpholino
oligomers (PMOs), which target EBOV-specific tran-
scripts, confer partial protection to infected rodents and
rhesus macaques. In this report, we describe the efficacy
of a new class of positively charged PMOs (PMO+).
Methods
Using established rodent models of EBOV and MARV
infections, we screened virus-specific PMO+ agents to
identify combinations capable of protecting against
lethal challenge. Efficacious PMO+ combinations were
further evaluated in non-human primate models of filo-
virus infection.
Results
In EBOV models of infection, PMO+ molecules specific
to EBOV VP35 and VP24, the combination of which is
designated as AVI-6002, protected EBOV-infected mice
and guinea pigs. Delivered by a combination of subcuta-
neous (s.c) and intraperitoneal (i.p.) routes, AVI-6002
protected 5 out of 8 (63%) of EBOV Zaire-infected rhesus
macaques when delivered using a therapeutic regimen
(i.e. beginning post infection). Similar survival (60%;
3 out of 5 macaques) was observed in a separate study
when AVI-6002 was delivered intravenously (i.v.).
In MARV infections models, a combination treatment
containing a mixture of NP- and VP24-specific PMO+
agents, designated as AVI-6003, conferred a high degree
of protection to mice and guinea pigs challenged with
a lethal dose of MARV. Delivered using a therapeutic
regimen, AVI-6003 completely protected MARV-infected
cynomolgus macaques when delivered via s.c, i.v., or a
combination of s.c. and i.p. routes.
Discussion
AVI-6002 and AVI-6003 represent highly promising
therapeutic candidates for treatment of filovirus infec-
tions in humans.
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